Clinical trial
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring…
NCT00136942 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00136942 |
|---|---|
| Title | A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol |
| Official title | A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin |
| Acronym | ACTFAST SWISS |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hyperlipidemia |
| Intervention type | Drug |
| Interventions | Atorvastatin |
| Enrollment | 370 |
| Start date | Apr 1, 2005 |
| First posted | Aug 29, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: